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1 
2 
3 
4 
5 Abstract 
6 
7 
8 
9 Background: Striatal dysfunction has been proposed as a 
10 pathomechanism for negative symptoms in schizophrenia. There 
11 
12 
is consensus that negative symptoms can be grouped into the 
13 
14 two dimensions apathy and diminished expression. Recent 
15 
16 studies suggest that different neural mechanisms underlie 
17 
18 these dimensions, however, the relationship between regional 
19 
20 resting-state cerebral blood flow (rCBF) and negative symptom 
21 
22 dimensions has not been investigated. 
23 
24 Methods: 29 patients with schizophrenia and 20 healthy 
25 controls were included. rCBF in the striatum was measured 
27 
using arterial spin labeling (ASL) magnetic resonance imaging. 
28 
29 Negative symptoms were assessed using the Brief Negative 
30 
31 Symptom Scale. 
32 
33 Results: The rCBF in the ventral and dorsal striatum was not 
34 
35 different between patients with schizophrenia and controls. 
36 
37 However, in the patients a positive association between the 
38 
39 severity of apathy and increased rCBF in the ventral and 
40 
41 dorsal striatum was found. This effect was not present for 
42 diminished expression. 
43 
44 
Limitations: Since all patients were medicated with atypical 
45 
46 antipsychotics, an impact of antipsychotic medication on rCBF 
47 
48 cannot be excluded, although we did not find a significant 
49 
50 association between rCBF and chlorpromazine equivalents. 
51 
52 Conclusion: The main finding of this study is a specific 
53 
54 association between increased striatal rCBF and the negative 
55 
56 symptom dimension of apathy. Our results further support a 
57 separate assessment of apathy and diminished expression when 
60  
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1 
2 
3 investigating the neural basis of negative symptoms. ASL can 
4 
5 provide a direct and quantitative technique to investigate the 
6 role of rCBF changes in the pathophysiology of negative 
7 
8 
symptoms. 
9 
10 
11 
12 
13 
14 
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16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
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28 
29 
30 
31 
32 
33 
34 
35 
36 
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38 
39 
40 
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1 
2 
3 
4 
5 Introduction 
6 
7 
8 
9 Striatal dysfunction has been hypothesized to be a fundamental 
10 mechanism underlying symptoms of schizophrenia for decades.
1  
A 
11 
12 
robust finding in the literature regards an increased striatal 
13 
14 dopamine synthesis in schizophrenia measured with positron 
15 
16 emission tomography and single-photon emission computed 
17 
18 tomography.
2,3  
Studies using functional magnetic resonance 
19 
20 imaging (fMRI) to assess striatal response to rewards have 
21 
22 shown a decreased signal in unmedicated patients.
4–6  
Results in 
23 
24 medicated patients are heterogenous,
7–9  
indicating a complex 
25 relationship between dopamine dysregulation and fMRI findings. 
27 
28 
29 More recently, it has been suggested that an increase in 
30 
31 dopamine turnover could be accompanied by an increased 
32 
33 perfusion of striatal areas.
10,11  
Arterial spin labeling imaging 
34 
35 (ASL) allows to obtain an absolute measure of regional 
36 
37 cerebral blood flow (rCBF). Previous studies indeed suggest an 
38 
39 increase in striatal rCBF in patients with schizophrenia
11–14  
and 
40 a high risk for psychosis,
15  
but findings are not fully 
42 
consistent
11,16–18  
and further research is clearly needed. 
43 
44 
45 
46 Schizophrenia is a disorder with heterogeneous symptom 
47 
48 expression along its course and negative symptoms have been 
49 
50 found to have a strong impact on long-term morbidity and poor 
51 
52 functional outcome.
19,20  
There is now a consensus that negative 
53 
54 symptoms can be dissociated into two dimensions: 
21–23  
A 
55 
56 motivational dimension consists of anhedonia, avolition and 
57 asociality and will be referred to as apathy. The second 
60  
37 
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1 
2 
3 dimension diminished expression combines the symptoms blunted 
4 
5 affect and alogia. In fMRI studies an association of ventral 
6 striatal hypoactivation with negative symptoms, in particular 
7 
8 
apathy, has repeatedly been reported.
8,24–26  
In addition, a recent 
9 
10 study found an association of dorsal striatal hypoactivation 
11 
12 in response to reward and apathy.
27
 
13 
14 
15 
16 It has to be kept in mind that these fMRI results do not 
17 
18 reflect absolute hypoactivation in the striatum, but a 
19 
20 decreased signal difference between rewarding and non- 
21 rewarding stimuli. Therefore, the absolute measure of rCBF 
22 
23 
provided by ASL can offer additional information on the neural 
24 
25 basis of symptoms. Most studies investigating ASL have not 
26 
27 focused specifically on the striatum, but have used whole 
28 
29 brain analysis approaches.
12,14,28  
Nevertheless, a few studies 
30 
31 have reported associations of striatal rCBF with symptoms: 
32 
33 Kindler et al.
11  
showed a positive correlation between striatal 
34 
35 rCBF and positive symptoms in patients with treatment 
36 resistant auditory hallucinations. Zhuo et al.
16  
found 
38 
increased rCBF in striatal and auditory areas in patients with 
39 
40 auditory verbal hallucinations. 
41 
42 
43 
44 In addition to these ASL studies on rCBF in the striatum, 
45 
46 earlier PET studies have reported an association of negative 
47 
48 symptoms with reduced rCBF at rest and during an attentional 
49 
50 task in frontal and parietal regions.
29–31  
However, these studies 
51 
52 did not address the distinction between apathy and diminished 
53 expression. Liemburg et al.
32  
found apathy to be related to 
54 
55 
abnormal activation in parietal and thalamic regions during a 
56 
57 planning task, but did not specifically investigate striatal 
60  
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1 
2 
3 rCBF. Overall, negative symptoms seem to be associated with 
4 
5 reduced rCBF in particular in frontal regions, but regional 
6 specificity remains to be determined. 
7 
8 
9 
10 The main goal of this study was to investigate the association 
11 
12 of striatal rCBF with negative symptoms. There is evidence 
13 
14 that the two negative symptom dimensions apathy and diminished 
15 
16 expression show differential associations with behavioral
33,34
 
17 
18 and neurobiological correlates, suggesting differences in 
19 
20 pathophysiology. Therefore, this distinction is of high 
21 relevance when investigating striatal rCBF. The paucity of 
22 
23 
reported associations of striatal rCBF with negative symptoms 
24 
25 might result from the fact that until now apathy and 
26 
27 diminished expression have not been addressed separately, 
28 
29 although the striatum might play very different roles in their 
30 
31 pathophysiology. 
32 
33 
34 
35 Based on the extant, albeit limited, evidence for increased 
36 striatal resting-state rCBF in patients with schizophrenia,
24,26
 
38 
our first hypothesis was that these patients would show 
39 
40 increased rCBF in the ventral and dorsal striatum compared to 
41 
42 controls. Our second and main hypothesis was that the negative 
43 
44 symptom dimension apathy would be associated with altered rCBF 
45 
46 in the ventral and dorsal striatum. As no study has previously 
47 
48 reported striatal rCBF in relation to specific dimensions of 
49 
50 negative symptoms, no predictions of directionality of the 
51 
52 effects could be made. 
53 
54 
55 Methods 
56 
57 
60  
26 
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1 
2 
3 Participants 
4 
5 
6 
Twenty-nine patients with schizophrenia and twenty healthy 
7 
8 
controls matched on a group level for age and sex were 
9 
10 included in the present study. Patients were recruited from 
11 
12 outpatient and inpatient units of the Psychiatric Hospital of 
13 
14 the University of Zurich and affiliated institutions. Healthy 
15 
16 controls were recruited from the community via advertisement. 
17 
18 
19 
20 For confirmation of the diagnosis the Mini-International 
21 
22 Neuropsychiatric Interview was conducted.
35  
Patients were 
23 
24 clinically stable and were under a stable dose of medication 
25 for at least two weeks prior to testing. Inpatients were at 
27 
the end of their hospitalization engaging in a multimodal 
28 
29 therapy program and activities outside the hospital. Please 
30 
31 note that the average duration of hospitalization for patients 
32 
33 with schizophrenia in Swiss psychiatric hospitals is longer 
34 
35 than in most other countries, so the majority of patients 
36 
37 would have been treated as outpatients in other health care 
38 
39 systems. Exclusion criteria for patients were any other DSM-IV 
40 
41 Axis I disorder, acute psychotic symptoms (i.e. scores higher 
42 than 4 on the positive subscale of the Positive and Negative 
43 
44 
Syndrome Scale PANSS
36
), extrapyramidal side effects (i.e. a 
46 
47 total score higher than 2 on the Modified Simpson-Angus Scale 
48 
49 MSAS
37
) and lorazepam medication higher than 1mg per day. If 
50 
51 the criteria for abuse or dependency of cannabis were met, the 
52 
53 patients were excluded from the study. Furthermore, 
54 
55 participants were excluded, if they had any alcohol use 
56 disorder based on lifetime criteria. 
57 
60  
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1 
2 
3 Smoking was not an exclusion criterion, but participants did 
4 
5 not smoke for two hours before the ASL-scans were conducted. 
6 
7 
8 
Healthy controls were excluded if any neuropsychiatric 
9 
10 diagnosis was present in the structured Mini-International 
11 
12 Neuropsychiatric Interview.
35  
In both groups participants with 
13 
14 neurological disorders were excluded. 
15 
16 
17 
18 The Ethics Committee of the Canton of Zurich approved the 
19 
20 project and participants gave written informed consent to 
21 participation in the study. The capability of each participant 
22 
23 
with schizophrenia to give informed consent was evaluated by 
24 
25 the treating psychiatrist. 
26 
27 
28 
29 
30 
31 Clinical and neuropsychological assessment 
32 
33 
34 
35 Negative symptoms were assessed using the Brief Negative 
36 Symptom Scale (BNSS).
38  
The two factors of negative symptoms 
38 
were calculated as follows: The apathy dimension consists of 
39 
40 the anhedonia, avolition and asociality items and the 
41 
42 diminished expression dimension includes the blunted affect 
43 
44 and alogia items.
39  
Other assessment instruments used were the 
45 
46 PANSS,
36  
the Calgary Depression Scale for Schizophrenia 
47 
48 (CDSS),
40  
the Global Assessment of Functioning Scale (GAF)
41  
and 
49 
50 the Personal and Social Performance Scale (PSP).
42  
Cognition 
51 
52 was assessed with a brief neurocognitive test battery (see our 
53 previous studies
33,34  
for details), which was used to compute a 
54 
55 
composite cognitive ability score for each participant. The 
56 
57 following domains were included in the battery: verbal 
60  
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1 
2 
3 learning, verbal and visual short-term and working memory, 
4 
5 processing speed, planning, and semantic and phonemic fluency. 
6 
7 
8 
9 
10 MRI data acquisition 
11 
12 
13 
14 MR data were acquired on a Philips Achieva 3.0T whole-body 
15 
16 scanner (Best, The Netherlands). We employed resting state 
17 
18 pseudo-continuous ASL (pCASL) perfusion-weighted scans. Due to 
19 
20 superior signal-to-noise ratio, pCASL is considered a more 
21 reliable method, compared to other ASL sequences.
43,44  
The 
22 
23 
imaging parameters for the pCASL were based on the sequence 
24 
25 developed by Dai et al., 2008.
45  
The plane was positioned 
26 
27 parallel to the imaging volume with a 20 mm labeling gap 
28 
29 between the imaging volume and the labeling volume. ASL 
30 
31 Parameters for the single shot gradient echo EPI sequence 
32 
33 were: repetition time (TR): 4400 ms; echo time (TE): 20 ms; 
34 
35 flip angle: 90°, FOV: 240 × 161 x 240 mm; spacing: 3 mm, 
36 matrix size: 80, 23 slices with slice thickness of 7 mm and no 
38 
gap; SENSE 2.5; post-labeling delay of 1525 ms; label 
39 
40 duration: 1650 ms; number of dynamics: 75 (duration 667.9 s). 
41 
42 One dynamic consisted of a control and a labeled image. 
43 
44 Additionally, high-resolution anatomical images (TR = 8.1 ms, 
45 
46 TE: 3.7 ms, FOV = 240 x 240 mm
2
, voxel size, 1 × 1 × 1 mm) were 
47 
48 acquired using a standard T1-weighted 3D magnetization 
49 
50 prepared rapid gradient echo sequence (MP-RAGE). 
51 
52 
53 
54 
55 
CBF calculation 
56 
57 
60  
5 
Page 11 of 39 Submitted to Journal of Psychiatry and Neuroscience 
 
 
1 
2 
3 Image data processing and analysis were performed using the 
4 ASLtoolbox
46  
running in MATLAB (The MathWorks Inc., Natick, MA, 
6 
2000) and compatible with the Statistical Parametric Mapping 
7 
8 
software (SPM12, Wellcome Trust Centre for Neuroimaging, UK 
9 
10 implemented in Matlab, Math Works, Natick, MA). For each 
11 
12 participant, image preprocessing was conducted including 
13 
14 realignment independently for labeled and unlabeled images, 
15 
16 spatial smoothing (6 x 6 x 14 mm kernel), perfusion weighted 
17 
18 image construction and calculation, and normalization to the 
19 
20 Montreal Neurological Institute MNI template (for ASL data, 
21 
22 rCBF calculations should be performed prior to spatial 
23 
24 normalization
46
). Equilibrium brain tissue magnetization (M0) 
25 
26 images were recorded in a separate run for each subject using 
27 
28 the same parameters as described for the pCASL sequence, apart 
29 from the TR (10 s). Next, unique cerebral spinal fluid M0 
30 
31 
values were calculated per participant for each session (and 
32 
33 corrected for T2* decay using a T2* value of 74.9 ms) and the 
34 
35 relevant H
2
O partition coefficient was taken from the 
36 
37 literature
47  
and considered in the calculation of each 
38 
39 perfusion weighted image. Perfusion weighted image series were 
40 
41 generated by simple subtraction of the label and control 
42 
43 images, followed by conversion to absolute mean rCBF image 
44 series. 
45 
46 
47 
48 
49 
50 
51 
52 Region of interest image analysis 
53 
54 
55 
56 Predefined regions of interest (ROIs) for the ventral and 
57 
60 
 
58 dorsal striatum were derived based on previous key 
59 
60  
Confi 
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1 
2 
3 publications using fMRI (see Fig. 1). As in the study of Yip 
4 and colleagues,
48  
for the ventral striatum ROI coordinates 
6 
(MNI) were defined according to a meta-analysis by Knutson and 
7 
8 
Greer
49  
(left: x=−12, y=10, z=−2; right: x=10, y=8, z=0, both 
9 
10 9mm spheres), which have also been used in our previous 
11 
12 studies.
25,50  
Coordinates for the dorsal striatum ROI were also 
13 
14 adopted from the recent study by Yip et al.
48
 
15 
16 (left: x=−9, y=3, z=15; right: x=9, y=3, z=15, both 9mm 
17 
18 spheres). The ROIs were generated with the Wake Forest 
19 
University Toolbox.
51  
For each ROI (VS-ROI, DS-ROI) mean rCBF 
21 
was extracted using the MARSBAR toolbox 
22 
23 
(http://marsbar.sourceforge.net). 
24 
25 To compare the mean cortical (grey matter masked) CBF between 
26 
27 groups, we extracted the mean CBF for each group from 90 
28 
29 cortical brain regions (AAL atlas, 
30 
31 http://neuro.imm.dtu.dk/wiki/Automated_Anatomical_Labeling) 
32 
33 and applied an unpaired two-tailed t-test. 
34 
35 
36 
37 
38 
Statistical analysis 
39 
40 
41 
42 Statistical analyses were computed using IBM SPSS Statistics 
43 
44 version 22. Demographic comparisons were tested with a 
2  
test, 
45 
46 
t-tests and Mann-Whitney U-tests if the criterion of normal 
47 
48 distribution was not met. To test our first hypothesis t-tests 
49 
50 were calculated for group comparisons of rCBF between patients 
51 
52 and controls for each ROI (ventral and dorsal striatum). 
53 
54 Normal distribution was confirmed with a Shapiro-Wilk test and 
55 
56 homogeneity of variances was tested using Levene's test. Both 
57 
20 
60 
 
58 assumptions were met in the current sample. Furthermore, 
59 
60  
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1 
2 
3 ANCOVAs were calculated to control for potential 
4 
5 sociodemographic differences between the patient and control 
6 group. 
7 
8 
9 
10 To test the main hypothesis Spearman correlation coefficients 
11 
12 (r
s
) were calculated between negative symptoms (apathy and 
13 
14 diminished expression) and rCBF in the ventral and dorsal 
15 
16 striatum. A Steiger's z-test was used to test the difference 
17 
18 between the two negative symptom dimensions as dependent 
19 
20 variables and rCBF as the common independent variable. 
21 
22 
23 
To address potentially confounding factors in the patient 
24 
25 group we calculated Spearman correlation coefficients between 
26 
27 rCBF in the ventral and dorsal striatum and age, positive 
28 
29 symptoms, chlorpromazine equivalents, depressive symptoms and 
30 
31 cognitive impairments via the composite cognitive ability 
32 
33 score. Only age showed a significant association with rCBF as 
34 
35 well as apathy. Therefore, non-parametric partial correlations 
36 were calculated to account for the effects of age on the 
38 
correlation between negative symptoms and rCBF. 
39 
40 All primary analyses reported above regard bilateral striatal 
41 
42 regions, because we had no a priori hypotheses regarding 
43 
44 differences between left and right striatum. 
45 
46 
47 
48 Results 
49 
50 
51 
52 Demographic and clinical characteristics 
53 
54 
55 
Demographic and clinical data are summarized in Table 1. The 
56 
57 groups did not show significant differences with regard to age 
60  
37 
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1 
2 
3 and sex. Healthy controls had a higher educational level and 
4 
5 cognitive scores. 
6 The following antipsychotic monotherapies were taken by the 
7 
8 
patient group: Clozapine (2 patients), olanzapine (1 patient), 
9 
10 quetiapine (2 patients) amisulpride (2 patients), risperidone 
11 
12 (7 patients), paliperidone (2 patients), aripiprazole (2 
13 
14 patients). Several patients took a combination of 
15 
16 antipsychotic medication: Clozapine and aripiprazole (1 
17 
18 patient), clozapine and amisulpride (1 patient), olanzapine 
19 
20 and aripiprazole (1 patient), olanzapine and quetiapine (1 
21 patient), olanzapine and risperidone (1 patient), amisulpride 
22 
23 
and quetiapine (1 patient), risperidone and quetiapine (3 
24 
25 patients), risperidone and aripiprazole (1 patient), 
26 
27 aripiprazole and quetiapine (1 patient). 
28 
29 
30 
31 
32 
33 CBF differences between groups 
34 
35 
36 
To test our first hypothesis we compared rCBF between groups 
38 
in the ventral and dorsal striatum. Patients and healthy 
39 
40 controls did not differ significantly in rCBF in the ventral 
41 
42 striatum and in the dorsal striatum (see Table 2). Thus, the 
43 
44 hypothesis that patients with schizophrenia would show altered 
45 
46 rCBF in the striatum could not be confirmed. 
47 
48 After controlling for educational level and cognitive score 
49 
50 patients with schizophrenia showed a trend towards higher rCBF 
51 
52 in the ventral striatum (F(1,45)= 3.37, p= .07), but not the 
53 
dorsal striatum (F(1,45)= 1.89, p= .18). 
54 
55 
56 
57 
60  
37 
Page 15 of 39 Submitted to Journal of Psychiatry and Neuroscience 
 
 
1 
2 
3 To control for differences in total grey matter CBF between 
4 
5 patients (m = 41.4 ml/100mg/min; SD = 8.8) and controls (m = 
6 41.7 ml/100mg/min; SD = 8.7) a t-test was calculated, which 
7 
8 
showed no significant differences between groups (t (47) = 
9 
10 .11; p = .91). We additionally addressed potential differences 
11 
12 in total grey matter volume between patients (m = 671.8 mm
3
; SD 
13 
14 = 51.4) and controls (m = 677.7 mm
3
; SD = 46.23), which showed 
15 
16 no significant differences between groups (t (47) = .41; p = 
17 
18 .68). 
19 
20 
21 
No participants had to be excluded because of excessive 
22 
23 
motion. Patients and control group did not differ 
24 
25 significantly on motion parameters. 
26 
27 
28 
29 Correlation between CBF and negative symptoms 
30 
31 
32 
33 To test our main hypothesis we calculated Spearman 
34 
35 correlations between rCBF of the striatum and the two negative 
36 symptom dimensions in the patient group (see Table 3). A 
38 
significant positive correlation was found between the ventral 
39 
40 striatal rCBF and apathy (see Fig. 2a and Table 3) as well as 
41 
42 dorsal striatal rCBF and apathy (see Fig. 2b and Table 3). 
43 
44 This finding provides evidence that patients with more apathy 
45 
46 show higher rCBF in the striatum. No significant correlation 
47 
48 was found between ventral striatum and diminished expression 
49 
50 (see Fig. 2c and Table 3) and dorsal striatum and diminished 
51 
52 expression (see Fig. 2d and Table 3). The results of Steiger's 
53 z-Test were nearly significant (ventral striatum: z= 1.88, p= 
54 
55 
.06; dorsal striatum: z= 1.73, p= .08). In other words, these 
56 
57 results suggest that the correlation between rCBF and apathy 
60  
Confidential 
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1 
2 
3 was stronger than the correlation between rCBF and diminished 
4 
5 expression. Concerning the BNSS total score, we observed a 
6 trend-level correlation with rCBF in the dorsal striatum (r= 
7 
8 
.34; p= .07, df= 27), but not in the ventral striatum (r= .20; 
9 
10 p= .29, df= 27). 
11 
12 
13 
14 rCBF did not correlate significantly with the following 
15 
16 potentially confounding variables: PANSS positive factor, CDSS 
17 
18 for depressive Symptoms, chlorpromazine equivalents, and the 
19 
20 composite cognitive ability score (see Table 4). Significant 
21 positive correlations were found between age and rCBF of the 
22 
23 
ventral and dorsal striatum. Therefore, non-parametric partial 
24 
25 correlations were calculated to control for effects of age on 
26 
27 the correlation of rCBF with apathy. The association between 
28 
29 apathy and rCBF in the dorsal striatum was at trend-level (r= 
30 
31 .34, p= .08, df= 26), while the association with the ventral 
32 
33 striatum was no longer significant (r= .25, p= .19, df= 26). 
34 
35 
36 
All primary analyses reported above regard bilateral striatal 
38 
regions, because we had no a priori hypotheses regarding 
39 
40 differences between left and right striatum. In an exploratory 
41 
42 analysis we compared the associations of left and right 
43 
44 striatum with apathy as well as diminished expression, which 
45 
46 showed the same pattern of results as the bilateral analysis 
47 
48 (see Table 3). 
49 
50 Furthermore, an exploratory voxel-wise analysis of rCBF in the 
51 
52 prefrontal cortex and anterior cingulate cortex was performed. 
53 The statistical threshold was set at a peak-level family-wise 
54 
55 
error (FWE) rate correction of p = .05. We found no voxels to 
56 
57 be significantly associated with apathy in the patient group. 
60  
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1 
2 
3 
4 
5 
6 
Discussion 
7 
8 
9 
10 In the present study we observed no significant differences in 
11 
12 striatal rCBF between patients with schizophrenia and healthy 
13 
14 controls. Importantly, the negative symptom dimension apathy - 
15 
16 but not diminished expression - was associated with dorsal 
17 
18 striatal rCBF and to a lesser extent ventral striatal rCBF. 
19 
20 
21 
Our first hypothesis concerning group differences could thus 
22 
23 
not be confirmed. This is at odds with some studies reporting 
24 
25 increased striatal rCBF in patients with schizophrenia
11,12,14,16
 
26 
27 whereas other studies did not observe these effects.
17,18
 
28 
29 Potential explanations for these differences between studies 
30 
31 include differences in image acquisition and data analysis. 
32 
33 Most importantly, the patient populations differ in numerous 
34 
35 aspects. In our study inclusion and exclusion criteria were 
36 specified in order to primarily assess negative symptoms. 
38 
Thus, our patients had low levels of positive symptoms. In 
39 
40 contrast, patients in the Kindler et al.
11  
study had treatment 
41 
42 resistant auditory hallucinations. Another important factor 
43 
44 might be the type of treatment with antipsychotic 
45 
46 medication.
14,52,53  
In our study all patients were treated with 
47 
48 atypical antipsychotic medication which in fMRI studies has 
49 
50 been shown to attenuate group differences in striatal 
51 activation.
4,8,25
 
53 
54 
55 
Regarding our main hypothesis the patient data showed a 
56 
57 significant association between the severity of apathy and 
60  
37 
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1 
2 
3 rCBF of both ventral and dorsal striatum, a relationship that 
4 
5 was not found for the symptom dimension of diminished 
6 expression. This differential effect for the two negative 
7 
8 
symptom dimensions might account at least in part for the lack 
9 
10 of consistent previous findings regarding rCBF correlates of 
11 
12 negative symptoms. In our study, an aggregation of overall 
13 
14 negative symptoms would have led to a non-significant finding. 
15 
16 The only other ASL study specifically assessing apathy 
17 
18 concerns rCBF during planning task performance, during which 
19 
reduced parietal and thalamic perfusion was observed.
32
 
21 
However, striatal perfusion was not reported and the 
22 
23 
comparison with our resting state approach is difficult. It 
24 
25 seems to be important for future ASL studies to assess both 
26 
27 dimensions of negative symptoms separately since different 
28 
29 neural mechanisms may be underlying these symptoms.
21,33,54
 
30 
31 
32 
33 While the distinction between the two negative symptom 
34 
35 dimensions apathy and diminished expression has received very 
36 limited interest in previous ASL studies, the blood oxygen 
38 
level dependent (BOLD)-fMRI literature has provided evidence 
39 
40 for a dissociation of their neural correlates. For instance, 
41 
42 Kirschner et al.
25  
reported reduced activity in the ventral 
43 
44 striatum during reward anticipation, which correlated with 
45 
46 apathy, but not diminished expression. For the dorsal striatum 
47 
48 an association between reduced activity and avolition, but not 
49 
50 anhedonia, has been shown. Importantly, in these fMRI studies 
51 
52 reduced activity reflects attenuated signal differences 
53 between rewarding and non-rewarding stimuli. Therefore, an 
54 
55 
association of apathy with both a reduced task-related fMRI 
56 
57 
20 
60  
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1 
2 
3 signal and increased resting-state rCBF in the striatum is not 
4 
5 contradictory. 
6 
7 
8 
At this point a mechanistic explanation for the association of 
9 
10 apathy and striatal rCBF remains somewhat speculative. Several 
11 
12 studies found increased rCBF in the striatum to be related to 
13 
14 higher dopaminergic activity.
55,56  
In addition, one PET study 
15 
16 reported an association of increased dorsal striatal dopamine 
17 
18 release with negative symptoms,
57  
which might seem at odds with 
19 
20 the observation that decreased dopamine availability can lead 
21 to apathy in neurological patients and animal models.
57–59
 
22 
23 
However, the hypothesis of aberrant salience attribution in 
24 
25 schizophrenia proposes that increased dopaminergic activity in 
26 
27 the striatum leads to difficulties in distinguishing between 
28 
29 relevant and irrelevant stimuli.
60,54  
This model has also been 
30 
31 employed to account for the attenuated striatal reward signal 
32 
33 in fMRI studies that has been shown to be associated with 
34 
35 negative symptoms.
61  
Thus, this inability to differentiate 
36 relevant and in particular rewarding stimuli can potentially 
38 
lead to a decrease in goal-directed behavior and promote 
39 
40 apathy.
62
 
41 
42 
43 
44 We found no significant correlation between positive symptoms 
45 
46 or cognition and striatal rCBF. Regarding positive symptoms it 
47 
48 has to be kept in mind that the aim of the study was to 
49 
50 investigate neural correlates of negative symptoms and 
51 
52 patients with significant positive symptoms were excluded, 
53 thereby considerably reducing variance. Cognitive deficits 
54 
55 
were not an exclusion criterion, but patients had to be able 
56 
57 to take part in this relatively demanding study and the 
60  
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1 
2 
3 overall cognitive performance of the patient group was less 
4 
5 than one standard deviation below the control group. 
6 
7 
8 
It may surprise that we did not find a significant group 
9 
10 difference in rCBF of the striatum in spite of the 
11 
12 relationship between apathy and striatal rCBF. It has to be 
13 
14 noted that striatal rCBF was slightly higher in patients, 
15 
16 although this difference was not significant. This type of 
17 
18 pattern can best be explained by a difference between patients 
19 
20 and controls that is only present for patients with a high 
21 level of apathy. In addition, treatment with antipsychotics 
22 
23 
might attenuate group differences in striatal rCBF to some 
24 
25 extent.
63
 
26 
27 
28 
29 It is of note that we observed higher age to be associated 
30 
31 with reduced striatal rCBF and lower apathy, although effects 
32 
33 of age have not been reported in previous studies of patients 
34 
35 with schizophrenia. However, our finding is consistent with 
36 previous reports of a reduction of rCBF with increasing age in 
38 
healthy subjects.
64,65  
Interestingly, a finding of a negative 
39 
40 relationship between age and negative symptoms as well as 
41 
42 white matter integrity measured by diffusion tensor imaging is 
43 
44 discussed in a paper by Bijanki et al.,
66  
that emphasizes the 
45 
46 necessity to include age as a confounding variable. Our 
47 
48 finding, that younger patients showed stronger apathy than 
49 
50 older participants might seem somewhat surprising, but is 
51 consistent with the study by Bijanki and colleagues.
66  
Overall, 
53 
the inclusion of age in partial correlations of apathy and 
54 
55 
striatal rCBF attenuated the association, but the effect in 
56 
57 the dorsal striatum remained at trend-level. 
60  
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1 
2 
3 
4 
5 
6 
Limitations 
7 
8 
9 
10 This study provides evidence for a positive association 
11 
12 between increased striatal rCBF and the negative symptom 
13 
14 dimension of apathy. Several limitations have to be taken into 
15 
16 account in the interpretation of these findings. First, sample 
17 
18 size was moderate and our findings require replication in a 
19 
20 larger sample, which would also allow to further specify the 
21 impact of age on the observed associations. Second, our sample 
22 
23 
was recruited with the aim of investigating neural correlates 
24 
25 of negative symptoms and is thus not representative of the 
26 
27 whole population of patients with schizophrenia. It is 
28 
29 possible that different associations between symptoms and 
30 
31 striatal rCBF can be found in patients with higher levels of 
32 
33 positive or depressive symptoms. Third, all patients in our 
34 
35 study took second-generation antipsychotic medication. 
36 Previous research has suggested an influence of antipsychotic 
38 
medication on striatal rCBF.
52,63,67,68  
While we did not observe an 
39 
40 association of striatal rCBF and antipsychotic dose, this does 
41 
42 not exclude a potential impact of antipsychotic medication. 
43 
44 Thus, future studies should include non-medicated patients and 
45 
46 patients taking first-generation antipsychotics to generalize 
47 
48 the relationship between apathy and striatal activity to these 
49 
50 populations. 
51 
52 
53 
54 
55 
Conclusion 
56 
57 
60  
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1 
2 
3 The association between increased striatal rCBF and the 
4 
5 negative symptom dimension of apathy, but not diminished 
6 expression, provides further evidence for the assumption of 
7 
8 
different underlying neural bases. Hence, these dimensions 
9 
10 should be considered separately in future research on negative 
11 
12 symptoms. Furthermore, ASL seems to provide a direct and 
13 
14 quantitative technique to investigate negative symptoms 
15 
16 circumventing the limitations of task based measures often 
17 
18 employed for BOLD-fMRI and the invasiveness of positron 
19 
20 emission tomography and single-photon emission computed 
21 tomography. This may qualify ASL as an alternative technique 
22 
23 
for developing biomarkers reflecting the pathomechanisms of 
24 
25 negative symptoms. 
26 
27 
28 
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1 
2 
3 
4 Table 1: Demographics, psychopathological and clinical characteristics of study participants  
5 
6 Group; mean ± SD* 
7 
8 Characteristic 
Schizophrenia, 
9 
Control, Statistical 
10 Age, years 27.7 7.2 30.6 6.6 t (47)= 1.45 0.15 
11 Sex, female:male 7:22 6:14 
2
(1)= .21 0.65 
12 
13 Education, years 11.4 2.8 14.2 2.5 U= 101.5  ≤ 0.001 
14 Smoking, pack years 5.7 13.7 2.4 4.8 U= 239.5 .25 
15 Duration of illness, years 7.2 7.1 - - - 
16 
17 Age of onset, years 21.0 4.8 - 
- - 
18 Chlorpromazine equivalents, mg/d 497.7 407.4 - 
- - 
19 BNSS score 
20 Apathy (motivation and pleasure) 15.5 6.9 - 
- - 
22 Diminished  expression 8.6 7.0 - - - 
23 SANS score§ 
24 
Apathy 11.9 5.6 - - - 
26 Diminished  expression 10.4 9.6 - - - 
27 PANSS score¶ 
28 
Positive 6.4 2.5 - - - 
30 Negative 12.0 5.2 - - - 
31 Disorganized 4.7 2.0 - - - 
32 
Excited 4.5 0.7 - - - 
34 Depressed 5.4 2.4 - - - 
35 Total 47.7 10.2 - - - 
36 
CDSS total score 2.1 2.5 - - - 
38 GAF score 58.1 9.6 - - - 
39 PSP total score 58.2 9.1 - - - 
40 
 
42 MWT IQ 24.52 6.03 28.70 2.79 t (47)= 2.89  0.006 
43 BNSS= Brief Negative Symptom Scale; CDSS= Calgary Depression Scale for Schizophrenia; 
44 GAF= Global Assessment of Functioning; MWT IQ= Multiple Word Test Intelligence Quotient; 
45 PANSS= Positive and Negative Syndrome Scale; PSP= Personal and Social Performance 
46 Scale; SANS= Scale for the Assessment of Negative Symptoms; SD= Standard deviation. 
47 *Unless otherwise indicated. 
48 §Apathy includes avolition/apathy and anhedonia/asociality; diminished expression includes 
49 affective flattening or blunting and alogia. 
50 ¶Positive factor= P1, P3, P5, P9; negative factor= N1, N2, N3, N4, N6, G7; disorganized 
51 factor= P2, G5, N11; excited factor= P4, P7, G8, G14; depressed factor= G2, G3, G6. 
52 **Cognition data have been z-transformed based on the data of the control group for each 
53 test separately. The composite cognitive ability score was computed as the mean of the z- 
54 transformed test scores at the participant level.  
55 
56 
60  
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19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical test 
t (47)= -.91, p= .37 
t (47)= -.95, p= .35 
20 rCBF= regional cerebral blood flow; ROI= region of interest; VS= ventral striatum; DS= dorsal 
21 striatum; SD= standard deviation. 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
 
   Mean  SD     Mean  SD    
VS  33.8 7.9   31.5 9.3  
DS  28.4 9.1   26.1 7.8  
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1 
2 
3 Table 3: Spearman correlations between apathy and diminished expression with the left and 
4 right VS and DS  
5 Apathy Diminished  expression 
 
6 
7 
 
  rs (df = 27)  p     rs (df = 27) p  
8      
9 mean rCBF VS left+right  .38 .04 .02 .91 
10      
11 mean rCBF DS left+right  .48 .008 .17 .39 
12      
13 mean rCBF left VS  .32 .09 .009 .96 
14 
15 mean rCBF right VS 
 .40 .03  .003 .99 
16 mean rCBF left DS 
17 
 .44 .02  .19 .32 
18 mean rCBF right DS  .51 .005  .10 .61 
19 
20 rCBF= regional cerebral blood flow; VS= ventral striatum; DS= dorsal striatum; rs= Spearman 
21 correlation coefficient; df= degree of freedom. 
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56 Table 4: Spearman correlations between striatal rCBF and confounding variables as well as 
57 PANSS negative factor scores in patients with schizophrenia 
60  
Submitted to Journal of Psychiatry and Neuroscience Page 32 of 39 
 
 
1 
2 
3 mean rCBF ventral 
4   striatum  
 
 
 
mean rCBF dorsal 
  striatum  
 
5 
6 
 rs (df= 27) p rs (df= 27) p 
7 PANSS positive factor -.15 .44 -.24 .21 
8      
9 PANSS negative factor .17 .39 .30 .12 
10      
11 CDSS total score 
.23 .24 .35 .06 
12 
Chlorpromazine  equivalents 
13 
-.05 .80 -.17 .39 
14 Composite cognitive ability 
15 score 
.27 .17 .11 .58 
16 Age -.39 .04 -.50 .006 
17      
18 PANSS= Positive and Negative Syndrome Scale; CDSS= Calgary Depression Scale for 
19 Schizophrenia; rCBF= regional cerebral blood flow; rs= Spearman correlation coefficient; df= 
20 degree of freedom. 
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                                                      Figure 1: Region of interest (ROI) of the ventral (A) and dorsal (B) striatum. 
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53 Figure 2B: Spearman correlation (including significance test) of mean regional cerebral blood 
54 flow (rCBF) of the left and right dorsal striatum (DS) with apathy. BNSS = Brief Negative 
55 Symptom Scale. 
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55 Figure 2D: Spearman correlation (including significance test) of mean regional cerebral blood 
56 flow (rCBF) of the left and right dorsal striatum (DS) with diminished expression. BNSS=Brief Negative Symptom 
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36 Figure 1: Region of interest (ROI) of the ventral (A) and dorsal (B) striatum. 
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